COMP <GO>
SYRE vs MDGL // FORWARD P/E MULTIPLE
Spyre Therapeutics Inc. (NASDAQ) VS. Madrigal Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: SYRE 6
— MDGL 3
▲ FORWARD P/E MULTIPLE LEADER: SYRE
LAST: $95.51 (-1.09%) • MKT CAP: $10.08B
forward-pe
22.0x
LAST: $431.16 (+0.19%) • MKT CAP: $9.94B
forward-pe
24.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYRE VS. MDGL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYRE | MDGL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.00% | -29.70% | +9.70 | SYRE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.64% | -1.91% | +0.27 | SYRE | /fcf-yield <GO> |
| Operating Margin | — | -31.30% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -30.10% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 17.60% | 180.00% | -162.40 | MDGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 7.65 | +18.35 | SYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | MDGL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 30.1 | +27.20 | SYRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 1.08 | -0.19 | MDGL | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 22.0x | 24.0x | -2.00 | SYRE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.08B | $9.94B | $139.2M | SYRE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYRE REV | MDGL REV | SYRE GROSS % | MDGL GROSS % | SYRE FCF | MDGL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $586.8M | $958.4M | — | — | -$169.3M | -$190.0M |
| FY 2024 | $584.0M | $180.1M | — | 96.5% | -$157.4M | -$457.0M |
| FY 2023 | $886.0K | $1.07B | — | — | -$99.9M | -$324.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYRE // BETA 0.89
MDGL // BETA 1.08